NOVN.SW CHMP opinion: Thursday, September 17, 2026
Variation type II · FABHALTA · A grouped application consisting of: C.4: Update of sections 4.4, 4.5, and 5.2 of the SmPC in order to add drug-drug interaction information based on the results from study CLNP023C12101. This is a Phase 1 study evaluating the effect of multiple oral doses of iptacopa
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.